ADC Therapeutics (ADCT) Net Cash Flow (2020 - 2026)
ADC Therapeutics (ADCT) posted Net Cash Flow of -$30.3 million for Q1 2026, down 213.9% sequentially from $26.6 million in Q4 2025, and up 46.16% YoY from -$20.7 million in Q1 2025.
ADC Therapeutics (ADCT) Net Cash Flow (2020 - 2026) Analysis & Trends
ADC Therapeutics has reported Net Cash Flow for 7 years, with the latest figure at -$30.3 million in Q1 2026.
- Quarterly Net Cash Flow rose 46.16% year-over-year to -$30.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $36.2 million (up 191.09% YoY) and the FY2025 annual result came in at $10.2 million, up 136.77% from the prior year.
- Net Cash Flow declined to -$30.3 million in Q1 2026 per ADCT's latest filing, from $26.6 million in the prior quarter.
- Over five years, Net Cash Flow peaked at $69.7 million in Q2 2025 and troughed at -$56.3 million in Q1 2025.
- A 5-year average of -$13.9 million and a median of -$29.8 million in 2025 frame the typical range for Net Cash Flow.
- The sharpest annual moves came in 2023 and 2025: Net Cash Flow plunged 958.92% in 2023, then surged 215.45% in 2025.
- Over 5 years, Net Cash Flow stood at -$54.7 million in 2022, then soared by 41.53% to -$32.0 million in 2023, then advanced by 27.84% to -$23.1 million in 2024, then soared by 215.45% to $26.6 million in 2025, then slumped by 213.9% to -$30.3 million in 2026.
- According to Business Quant data, Net Cash Flow over the past three periods registered -$30.3 million, $26.6 million, and -$29.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | ADC Therapeutics | 154.55 Mn | -64.56 Mn | 17.14 Mn | -11.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -11.91 Mn |
| Jun 30, 2026 | -11.91 Mn |
| Mar 31, 2026 | -30.33 Mn |
| Mar 31, 2026 | -30.33 Mn |
| Dec 31, 2025 | 26.63 Mn |
| Dec 31, 2025 | 26.63 Mn |
| Sep 30, 2025 | -29.83 Mn |
| Sep 30, 2025 | -29.83 Mn |
| Jun 30, 2025 | 69.70 Mn |
| Jun 30, 2025 | 69.70 Mn |
| Mar 31, 2025 | -56.33 Mn |
| Mar 31, 2025 | -56.33 Mn |
| Dec 31, 2024 | -23.06 Mn |
| Dec 31, 2024 | -23.06 Mn |
| Sep 30, 2024 | -26.14 Mn |
| Sep 30, 2024 | -26.14 Mn |
| Jun 30, 2024 | 65.82 Mn |
| Jun 30, 2024 | 65.82 Mn |
| Mar 31, 2024 | -44.27 Mn |
| Mar 31, 2024 | -44.27 Mn |